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SUMMARY
Two classes of epidermal growth factor receptor (EGFR) inhibitors are currently available for clini-
cal use: tyrosine-kinase inhibitors (TKIs) and monoclonal antibodies. The introduction of phar-
macological agents that are able to inhibit EGFR represents an important step in the management 
of patients with advanced non-small cell lung cancer (NSCLC), the leading cause of cancer death 
worldwide. The use of EGFR inhibitors has not only led to meaningful therapeutic gains for pa-
tients, but has also expanded our knowledge about the disease itself, as it is now recognized that 
activating mutations of EGFR play a pathogenetic role in NSCLC, especially in adenocarcinoma, 
patients who never smoked or former light smokers, females, and Asian individuals. Patients with 
NSCLC and one or more of these features are more likely to harbor tumors with EGFR mutations, 
and hence to respond to TKIs, than individuals without these features. Currently, TKIs are consid-
ered by many as the treatment of first choice in both the first- and second-line treatment of patients 
with clinical or molecular predictors of therapeutic benefit, and chemotherapy is a second option 
in these cases, especially when activating mutations of EGFR are present. Moreover, TKIs and anti-
EGFR antibodies may be used in other settings, and their therapeutic role in NSCLC is clearly ex-
panding. However, despite an initially successful treatment course, patients with advanced NSCLC 
eventually develop resistance to TKIs; and novel agents that hold promise for the future include 
irreversible EGFR inhibitors with activity against resistance-conferring EGFR mutations. 
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RESUMO
Inibidores do receptor do fator de crescimento epidérmico  
no câncer de pulmão em células não pequenas: estado atual  
e prespectivas futuras
Duas classes de inibidores do receptor do fator de crescimento epidérmico (EGFR) estão atual-
mente disponíveis para uso clínico: inibidores de tirosina-quinase (TKI) e anticorpos monoclonais. 
A introdução de agentes farmacológicos capazes de bloquear o EGFR representa um passo impor-
tante no manejo de pacientes com câncer de pulmão de células não pequenas (CPCNP) avançado, 
principal causa de morte por câncer no mundo. Além dos benefícios clínicos significativos obtidos 
com os inibidores de EGFR, o uso desses agentes proporcionou um maior conhecimento sobre 
a doença, sendo agora reconhecido que mutações ativadoras de EGFR desempenham um papel 
patogenético importante no CPCNP, especialmente em adenocarcinomas, indivíduos não fuman-
tes, mulheres e asiáticos. Indivíduos com CPCNP e uma ou mais dessas características são mais 
propensos a apresentar tumores com mutações de EGFR e, portanto, a responder aos TKIs do que 
pacientes sem essas características. Atualmente, os TKIs são considerados por muitos como a es-
tratégia terapêutica de escolha na primeira e segunda linhas de tratamento de pacientes com fatores 
clínicos ou moleculares preditivos de benefício terapêutico, com a quimioterapia sendo vista como 
a segunda opção nesses casos, especialmente na presença de mutações ativadoras de EGFR. Além 
disso, TKIs e anticorpos anti-EGFR podem ser usados em outras situações, e seu papel no CPCNP 
está em clara expansão. No entanto, apesar de um curso de tratamento inicialmente bem-sucedido, 
pacientes com CPCNP avançado eventualmente desenvolvem resistência aos TKIs. Novos agentes 
promissores incluem inibidores irreversíveis de EGFR com atividade contra formas mutantes de 
EGFR que conferem resistência.
Unitermos: Receptor do fator de crescimento epidérmico; mutação; oncogenes; neoplasias pul-
monares.
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INTRODUCTION
Non-small cell lung cancer (NSCLC), which currently re-
presents nearly 85% of primary malignant lung tumors1, 
is the leading cause of cancer deaths worldwide2. Despite 
the potential benefits of improved diagnostic modalities, 
approximately 50% of patients with NSCLC present with 
advanced, incurable disease3,4. For such patients, treatment 
is performed with a palliative intent, and prognosis is still 
poor5. Cytotoxic chemotherapy, although able to improve 
the overall survival (OS) of patients with advanced NS-
CLC6, seems to have reached a plateau of efficacy nearly a 
decade ago7. In recent phase III trials among patients with 
advanced NSCLC, the median OS has typically ranged 
from only eight to 12 months8-10. Therefore, new treatment 
modalities have been thoroughly investigated in recent 
years, usually based on advances in our understanding of 
tumor biology11. Given the role of the epidermal growth 
factor receptor (EGFR) in the pathogenesis of NSCLC, 
inhibitors of this receptor have received the greatest atten-
tion, and have indeed been found to provide therapeutic 
benefits for certain patients12,13. This review summarizes 
the current knowledge regarding the role of EGFR inhi-
bitors in the treatment of patients with advanced NSCLC. 
PATHOGENETIC ROLE OF EGFR IN NSCLC
EGFR is a member of a family of closely-related membra-
ne receptors with intrinsic tyrosine-kinase activity14. The 
generic structure of the four known members of the hu-
man epidermal receptor (HER) family is shown in Figu-
re 1. Upon ligand binding to the extracellular portion of 
EGFR, receptor dimerization with another EGFR molecu-
le or with another member of this family (namely, HER-2, 
HER-3, or HER-4) leads to autophosphorylation of the in-
tracellular tyrosine-kinase domain of the receptor, which 
serves as a docking site to a series of adaptor molecules 
and kinases that are able to transduce the signal downs-
tream towards the nucleus. EGFR is overexpressed in the 
majority of lung tumors and is correlated with poor prog-
nosis, thus providing the rationale for the development of 
novel agents that target this receptor12.  
EGFR INHIBITORS: CHEMICAL CLASSES AND MODE 
OF ACTION
At least theoretically, the activity of EGFR may be inhibited 
at different molecular levels, including the EGFR gene, its 
messenger RNA, and the receptor protein itself13. To date, 
only receptor-targeting strategies have reached advanced 
phases of clinical development. Two classes of EGFR inhi-
bitors are currently available for clinical use in many coun-
tries: tyrosine-kinase inhibitors (TKIs) and monoclonal 
antibodies12. Both classes of agents exert antitumor activity, 
but their mode of administration and mechanism of action 
are different, with potential implications for clinical efficacy. 
Erlotinib and gefitinib are the TKIs currently approved in 
some countries for the treatment of advanced NSCLC. They 
are orally administered, quinazoline-derived adenosine tri-
phosphate (ATP) analogs that work by reversibly inhibiting 
the binding of ATP to the intracellular tyrosine-kinase do-
main of EGFR (Figure 1). As a result, downstream signaling 
by this receptor is reversibly blocked. Cetuximab is an in-
travenously administered monoclonal antibody that binds 
to the extracellular portion of EGFR, potentially blocking 
downstream signals from the receptor15. Binding of cetux-
imab leads to receptor endocytosis and degradation; in ad-
dition, cetuximab and other monocolonal antibodies may 
lead to antibody-dependent cell-mediated cytotoxicity and 
tumor eradication through immunological mechanisms14. 
 
CLINICAL DEVELOPMENT OF TKIS
HISTORICAL DEVELOPMENT AND THE ROLE OF EGFR MUTATIONS
Following extensive pre-clinical testing and phase I trials, 
both currently available TKIs provided encouraging results 
in phase II trials16-18. In those trials, erlotinib and gefitinib 
were used as single agents after the failure of conventional 
chemotherapy. Although the dose of 150 mg per day was 
established early in the development of erlotinib19, gefitinib 
was used at two dose levels (250 mg and 500 mg) in some 
of its phase II and phase III trials. The most common ad-
verse events resulting from the use of erlotinib and gefitinib 
are acneiform rash (most frequently involving the face and 
trunk) and diarrhea. Other adverse events are infrequent 
and seldom lead to treatment discontinuations.
Given the pre-clinical evidence for synergism between 
TKIs and chemotherapy20, a generation of phase III trials 
was launched in an attempt to evaluate whether the ad-
dition of TKIs to first-line chemotherapy would improve 
treatment results. Unfortunately, four phase III trials in-
volving a total of over 4,000 patients provided negative 
results in progression-free survival (PFS) and OS11,21-23. In 
spite of the negative results from phase III trials, it soon be-
came clear that the use of TKIs in clinical practice benefited 
some patients in a preferential manner24, 25. Those conflict-
ing observations appeared puzzling at the time and were 
explained only when the role of somatic EGFR mutations 
became evident26,27. Figure 1 –  Human epidermal receptor (HER) family.
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We now know that acquired mutations in the portion 
of the EGFR gene (exons 18 to 24) encoding the tyrosine-
kinase domain of the receptor confer sensitivity to TKIs. 
Such mutations, also called activating mutations, have 
been found in 15% to 40% of cases in various published 
studies28-32. Overall, activating EGFR mutations are more 
frequent in females, Asian individuals, and non-smokers31. 
Interestingly, these same features had been associated with 
an increased sensitivity to erlotinib and gefitinib in clinical 
trials, and the discovery of the correlation between their 
presence and EGFR mutations provided the missing link 
at the time16,17,33. Likewise, patients with adenocarcinoma 
as the histological subtype of NSCLC also appeared to de-
rive more benefit from TKIs16,17,33,34, and the demonstration 
that EGFR mutations are more common in individuals 
with adenocarcinoma eventually explained that observa-
tion31. Of note, adenocarcinoma is currently the most fre-
quent histological type of NSCLC in most studies, having 
thus surpassed squamous tumors35. 
SECOND- OR THIRD-LINE TREATMENT WITH TKIS
In parallel with the first-line studies, randomized trials 
continued to investigate TKIs as single-agents in second- 
or third-line therapy. Two phase III trials compared a TKI 
with placebo in patients with advanced disease previously 
treated with conventional chemotherapy36,37. Erlotinib was 
evaluated as second- or third-line therapy in patients with 
tumor-node-metastasis stage IIIB or IV NSCLC who had 
received one or two prior chemotherapy regimens, which 
were platinum-based in 93% of the cases36. A total of 731 
patients were randomized in a 2:1 ratio to receive either 
erlotinib or placebo. The median OS was 6.7 months with 
erlotinib and 4.7 months with placebo, translating into a 
relative reduction in the risk of death by 30% (p < 0.001). 
Gefitinib was assessed as second- or third-line treatment 
in a similar population of 1,692 patients who were rando-
mized in a 2:1 ratio to receive either TKI at the dose of 250 
mg per day or placebo37. There was no significant differen-
ce in OS between the two groups (median of 5.6 versus 
5.1 months; p = 0.087), but preplanned subgroup analyses 
showed significantly longer survival in the gefitinib group 
than in the placebo group for never-smokers and for pa-
tients of Asian origin. Gefitinib was also compared with 
chemotherapy in the treatment of patients whose disease 
had progressed after platinum-based regimens; in that set-
ting, gefitinib was found to be non-inferior to single-agent 
docetaxel in the largest phase III trial published to date in 
advanced NSCLC (n = 1,466)38.
FIRST-LINE TREATMENT WITH TKIS
The recognition of the predictive role of patient features 
and EGFR mutations led to the design of a second genera-
tion of first-line studies in which patients were selected on 
the basis of clinical or molecular features. Phase II trials 
of gefitinib as a single agent among such patients readily 
demonstrated encouraging results, with response rates ty-
pically ranging from 30% to 75%39-43. Moreover, the res-
ponse rates ranged from 55% to 75% when patients were 
selected for the presence of EGFR mutations40,42,43. Those 
results paved the way for phase III trials of gefitinib versus 
chemotherapy in patients selected for clinical44 or molecu-
lar features45. 
In the first study, Asian patients with adenocarcinoma 
who were non-smokers or former light smokers (defined 
as having stopped smoking at least 15 years prior and 
having a total of ≤ 10 pack-years of smoking) were ran-
domized to receive gefitinib (250 mg/day) or carboplatin 
plus paclitaxel44. 437 of the 1217 patients were tested for 
the presence of EGFR mutations. The primary objective 
of assessing the non-inferiority of gefitinib with respect to 
PFS was met; in addition, superiority of the TKI was dem-
onstrated in the intention-to-treat population (26% rela-
tive risk reduction; p < 0.001) and in the subgroup of 261 
patients with EGFR mutations (52% relative risk reduc-
tion; p < 0.001). On the other hand, the PFS was signifi-
cantly longer among patients treated with chemotherapy 
when EGFR mutations were absent, thus confirming the 
predictive role of these mutations. In the second study, 
patients with metastatic NSCLC and EGFR mutations 
were randomized to receive gefitinib or carboplatin plus 
paclitaxel45. In a planned interim analysis of the first 200 
patients, the PFS was significantly longer in the gefitinib 
group than in the chemotherapy group (64% relative risk 
reduction; p < 0.001), resulting in early termination of the 
study. Other study endpoints, such as response rate and 
OS, also favored the group treated with gefitinib.
MAINTENANCE TREATMENT WITH TKIS
The concept of maintenance treatment has recently gained 
greater acceptance in advanced NSCLC, despite the fact 
that improvements in OS have remained elusive in some 
studies46. A phase III trial among patients with stage IIIB 
or IV NSCLC whose disease had not progressed after four 
cycles of platinum-based first-line chemotherapy showed 
that erlotinib significantly prolonged the PFS and OS, 
with relative risk reductions of 29% and 19%, respecti-
vely47. In a second phase III trial, published thus far only in 
abstract form, maintenance treatment with erlotinib and 
bevacizumab [the anti-vascular endothelial growth factor 
(VEGF) antibody] was found to prolong the PFS, in com-
parison with single-agent bevacizumab, in advanced NS-
CLC; however, this combined regimen is still considered 
experimental48. 
CLINICAL DEVELOPMENT OF CETUXIMAB
Following extensive pre-clinical and phase I testing in 
various settings13, a series of phase II trials of cetuxi-
mab in combination with platinum-based chemotherapy 
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suggested a role for this approach in the first-line treat-
ment of advanced NSCLC49,50. When used as a single agent, 
the most important adverse events associated with cetuxi-
mab are acneiform rash, allergic reactions, and hypomag-
nesemia. Two phase III trials of cetuximab in advanced 
NSCLC have been reported to date51,52. In the FLEX trial, 
1,125 patients with advanced NSCLC and positive EGFR 
expression by immunohistochemistry were randomized 
to cisplatin-based chemotherapy alone or combined with 
cetuximab51. Patients given chemotherapy plus cetuximab 
had a median OS of 11.3 months, compared with 10.1 
months for those given chemotherapy alone (relative risk 
reduction of 13%; p = 0.044). There was no preferential be-
nefit in subgroups of patients defined by various demogra-
phic or clinical features. Of note, the addition of cetuximab 
had no effect on time to tumor progression, a secondary 
endpoint in the study. In the second phase III trial, the ad-
dition of cetuximab to carboplatin-based chemotherapy 
led to a significant improvement of response rate, but not 
of PFS, the primary endpoint of the study52. Taken toge-
ther, these results are less impressive than those seen with 
single-agent TKIs as first-line therapy for patients selected 
on the basis of clinical or molecular features44. However, 
cetuximab has been approved in some countries based on 
the FLEX trial.
RESISTANCE TO TKIS AND PERSPECTIVES FOR THE FUTURE
After the discovery of activating mutations, it soon beca-
me apparent that mutations in the tyrosine-kinase domain 
of EGFR were also associated with resistance to TKIs53. 
These somatic mutations represent a mechanism of ac-
quired resistance, as they have been found in tumors that 
were previously sensitive to reversible EGFR inhibition by 
erlotinib or gefitinib. Thus, despite an initial response to 
TKIs, patients with NSCLC harboring these mutations of-
ten manifest the acquired resistance within 6 to 12 months 
of therapy54. As reported by Pao et al., molecular analysis 
in patients with acquired resistance to gefitinib or erlotinib 
often discloses a secondary mutation in exon 20 of EGFR, 
which leads to substitution of methionine for threonine 
at position 790 (T790M) in the kinase domain55. Thus, 
T790M is considered the gatekeeper residue, an important 
determinant of inhibitor specificity within the ATP-bin-
ding domain of EGFR. Substitution of threonine at this 
residue with the bulky methionine may cause resistance 
by steric interference with binding of TKIs53,55. However, 
further research on this mutation has led to the sugges-
tion that it causes resistance by increasing the affinity for 
ATP56. Since these reports were first published, several stu-
dies have shown that the T790M mutation is often present 
before the patient starts therapy57, which suggests that it 
may confer a survival advantage during TKI treatment. 
Based on this knowledge, new inhibitors of EGFR 
have been developed in the attempt to overcome such 
resistance58. Thus, irreversible inhibitors of EGFR, such 
as afatinib59,60, have been developed and are presently un-
dergoing clinical trials. In addition, combined inhibitors 
of EGFR and other membrane receptors, such as the vas-
cular endothelial growth factor receptor (VEGF)61, hold 
promise for the future. On the other hand, it appears that 
the commercially available combined inhibitor of EGFR 
and HER-2 does not display clinically relevant activity in 
NSCLC62. Also, several other anti-EGFR antibodies, in-
cluding panitumumab, matuzumab, and nimotuzumab, 
have been developed and may theoretically be useful in 
the treatment of NSCLC63. At present, however, only ce-
tuximab has undergone clinical development to the point 
of being approved in some countries51.
There are other possible mechanisms of resistance to 
EGFR inhibitors. Met is a receptor protein that is mutated 
or overexpressed in many cancers, and is typically associ-
ated with a worse prognosis, including in NSCLC.  Impor-
tantly, Met has been identified as one of the mechanisms 
of resistance to EGFR TKIs over the last few years, and 
it appears to be involved both in primary resistance (i.e., 
from the very start of EGFR TKI therapy), and in acquired 
resistance after an initial response64,65. Furthermore, Met 
appears to be involved in resistance to cetuximab as well66.
CONCLUSIONS
The introduction of EGFR inhibitors represented an im-
portant step in the management of patients with advan-
ced NSCLC, both in terms of therapeutic gains and of the 
knowledge that resulted from the study of mutations that 
confer sensitivity and resistance to TKIs.  These agents 
have altered the overall approach to advanced NSCLC, 
particularly in cases of adenocarcinoma and tumors not 
associated with smoking. Currently, TKIs are considered 
by many as the first choice in the first- or second-line treat-
ment of patients with clinical or molecular predictors of 
therapeutic benefit, with chemotherapy being seen as a se-
cond option in these cases67. However, despite an initially 
successful course of treatment, patients with advanced 
NSCLC eventually develop resistance to TKIs, and novel 
agents are clearly needed. Moreover, ongoing studies are 
assessing the role of TKIs in other settings, such as an ad-
juvant treatment of early-stage NSCLC.
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